Pathways and strategies for developing a malaria blood-stage vaccine

Annual Review of Immunology

Volumn 16, Issue , 1998, Pages 57-87

  Good, Michael F ^a   Kaslow, David C ^b   Miller, Louis H ^b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Immune mechanisms; MSP 1; Pathogenesis

Indexed keywords

ANTIPARASITIC AGENT; ANTITOXIN; APICAL MEMBRANE ANTIGEN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 2; UNCLASSIFIED DRUG;

ANTIGENIC VARIATION; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; DRUG RESEARCH; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIFE CYCLE; MALARIA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMODIUM; PRIORITY JOURNAL; REVIEW; SPOROZOITE; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS; DRUG DESIGN; ERYTHROCYTES; HUMANS; LIFE CYCLE STAGES; MALARIA VACCINES; PLASMODIUM;

EID: 0031921082     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.16.1.57     Document Type: Review

References (15)

1. WHO Report. 1996. State of the World's Vaccines and Immunization. Geneva: World Health Org.
2. Cohen S, McGregor IA, Carrington S. 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192:733-37
3. Grun JL, Weidanz WP. 1981. Immunity to Plasmodium chabaudi adami in the B cell-deficient mouse. Nature 290:143-15
4. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-75
5. Nussenzweig V, Nussenzweig RS. 1989. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45:283-334
6. Stoute JA, Slaoui M, Heppner G, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, Ballou WR, Cohen JD. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336:86-91
7. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P. 1996. Attacking the infected hepatocyte. In Malaria Vaccine Development: A Multi-Immune Response Approach, ed. SL Hoffman, pp. 36-75. Washington, DC: Am. Soc. Microbiol.
8. Marsh K, Otoo L, Haynes RH, Carson DC, Greenwood BM. 1989. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83:293-303
9. Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, Carter R, Saul A. 1997. Measurement of Plasmodium falciparum growth rate in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57:495-500
10. Warrell DA, Molyneux ME, Beales PR 1990. Severe and complicated malaria. Trans. R. Soc. Trop. Med. 84 (Suppl.2):1-65
11. Miller LH, Good MF. Milon G. 1994. Disease pathogenesis in malaria. Science 264:1878-83
12. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstanley P, Warn P, Pasvol G, Snow R. 1995. Indicators of life-threatening malaria in African children. N. Engl. J. Med. 332:1399-1404
13. Molyneux ME, Taylor TE, Wirima JJ. Borgstein A. 1989. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q. J. Med. 71:441-59
14. Clark IA, Rockett KA, Cowden WB. 1991. Proposed link between cytokines, nitric oxide and human cerebral malaria. Parasitai. Today 7:205-7
15. Kwiatkowski D. Hill AV, Sambou I, Twumasi P, Castracane J, Manogue KR, Cerami A, Brewster DR, Greenwood BM. 1990. TNF concentrations in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336:1201-4